TG Therapeutics | TGTX - Trade Debtors


TG Therapeutics reported $231.52M in Trade Debtors for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 702.61M
Cash and Equivalent USD 278.86M
Cost of Sales USD 18.94M
Current Assets USD 663.96M
Current Liabilities USD 171.89M
Debt USD 8.98M
EBIT USD 34.84M
EBITDA USD 12.28M
Employees 338
EPS Earnings Per Share USD 0.17
Equity Capital and Reserves USD 276.43M
Gross Profit on Sales USD 122.21M
Interest Expense on Debt USD 6.72M
Loan Capital USD 245.04M
Market Capitalization USD 4.97B
Net Income USD 28.19M
Operating Expenses USD 106.31M
Operating Profit USD 34.84M
Ordinary Share Capital USD 158.03M
PE Price to Earnings USD 88.77
Pre-Tax Profit USD 30.92M
Sales Revenues USD 141.1M
Selling and Administration Expenses USD 12.04M
Stock USD 155.2M
Trade Creditors USD 134.02M
Trade Debtors USD 231.52M

Trade Debtors Change Date
AbbVie USD 12.48B 1.56B Mar/2025
Alaunos Therapeutics USD 5K 5K Dec/2024
Amgen USD 8.7B 569M Jun/2025
Ardelyx USD 62.55M 4.84M Jun/2025
Arrowhead Research USD 9.7M 7.33M Jun/2025
Bayer EUR 17.64B 895M Jun/2025
Biogen USD 2.08B 87.5M Jun/2025
Corcept Therapeutics USD 64.57M 2.75M Jun/2025
Dynavax Technologies USD 73.34M 16.79M Jun/2025
Gilead Sciences USD 4.78B 393M Jun/2025
J&J USD 16.02B 1.18B Mar/2025
Novartis USD 9.18B 451M Jun/2025
PTC Therapeutics USD 196.13M 14.36M Jun/2025
Regeneron Pharmaceuticals USD 5.61B 49M Jun/2025
Roche Holding CHF 13.46B 984M Dec/2024
TG Therapeutics USD 231.52M 102.33M Jun/2025
Vertex Pharmaceuticals USD 1.89B 88.4M Jun/2025